<?xml version='1.0' encoding='utf-8'?>
<document id="25996489"><sentence text="Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins." /><sentence text="During drug development, it is an important safety factor to identify the potential of new molecular entities to become a victim of drug-drug interactions (DDIs)" /><sentence text=" In preclinical development, however, anticipation of clinical DDIs remains challenging due to the lack of in vivo human pharmacokinetic data" /><sentence text="" /><sentence text="We applied a recently developed in vitro-in vivo extrapolation method, including hepatic metabolism and transport processes, herein referred to as the Extended Clearance Concept Classification System (ECCCS)" /><sentence text=" The human hepatic clearances and the victim DDI potentials were predicted for atorvastatin, cerivastatin, fluvastatin, lovastatin acid, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid"><entity charOffset="79-91" id="DDI-PubMed.25996489.s6.e0" text="atorvastatin" /><entity charOffset="93-105" id="DDI-PubMed.25996489.s6.e1" text="cerivastatin" /><entity charOffset="107-118" id="DDI-PubMed.25996489.s6.e2" text="fluvastatin" /><entity charOffset="120-135" id="DDI-PubMed.25996489.s6.e3" text="lovastatin acid" /><entity charOffset="137-149" id="DDI-PubMed.25996489.s6.e4" text="pitavastatin" /><entity charOffset="151-162" id="DDI-PubMed.25996489.s6.e5" text="pravastatin" /><entity charOffset="164-176" id="DDI-PubMed.25996489.s6.e6" text="rosuvastatin" /><entity charOffset="182-198" id="DDI-PubMed.25996489.s6.e7" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e6" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e0" e2="DDI-PubMed.25996489.s6.e7" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e1" e2="DDI-PubMed.25996489.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e1" e2="DDI-PubMed.25996489.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e1" e2="DDI-PubMed.25996489.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e1" e2="DDI-PubMed.25996489.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e1" e2="DDI-PubMed.25996489.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e1" e2="DDI-PubMed.25996489.s6.e6" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e1" e2="DDI-PubMed.25996489.s6.e7" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e2" e2="DDI-PubMed.25996489.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e2" e2="DDI-PubMed.25996489.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e2" e2="DDI-PubMed.25996489.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e2" e2="DDI-PubMed.25996489.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e2" e2="DDI-PubMed.25996489.s6.e6" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e2" e2="DDI-PubMed.25996489.s6.e7" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e3" e2="DDI-PubMed.25996489.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e3" e2="DDI-PubMed.25996489.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e3" e2="DDI-PubMed.25996489.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e3" e2="DDI-PubMed.25996489.s6.e6" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e3" e2="DDI-PubMed.25996489.s6.e7" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e4" e2="DDI-PubMed.25996489.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e4" e2="DDI-PubMed.25996489.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e4" e2="DDI-PubMed.25996489.s6.e6" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e4" e2="DDI-PubMed.25996489.s6.e7" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e5" e2="DDI-PubMed.25996489.s6.e5" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e5" e2="DDI-PubMed.25996489.s6.e6" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e5" e2="DDI-PubMed.25996489.s6.e7" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e6" e2="DDI-PubMed.25996489.s6.e6" /><pair ddi="false" e1="DDI-PubMed.25996489.s6.e6" e2="DDI-PubMed.25996489.s6.e7" /></sentence><sentence text="" /><sentence text="Hepatic statin clearances were well-predicted by the ECCCS with six out of eight clearances projected within a two-fold deviation to reported values" /><sentence text=" In addition, worst-case DDI predictions were projected for each statin" /><sentence text=" Based on the ECCCS class assignment (4 classes), the mechanistic interplay of metabolic and transport processes, resulting in different DDI risks, was well-reflected by our model" /><sentence text=" Furthermore, predictions of clinically observed statins DDIs in combination with relevant perpetrator drugs showed good quantitative correlations with clinical observations" /><sentence text="" /><sentence text="The ECCCS represents a powerful tool to anticipate the DDI potential of victim drugs based on in vitro drug metabolism and transport data" /><sentence text="" /></document>